Meridian Bioscience, Inc. (NASDAQ: VIVO) reported Q4 EPS of $0.21, $0.02 better than the analyst estimate of $0.19. Revenue for the quarter came in at $43.7 million versus the consensus estimate of $42.97 million.

For earnings history and earnings-related data on Meridian Bioscience, Inc. (VIVO) click here.

Earnings